$2,500 Full-Body MRI Scans Drawing Crowds for Early Cancer Detection.
In July last year, while celebrating Independence Day on a boat in Tyler, Texas, Dr. Julianne Santarosa received unsettling news from her $2,500 full-body MRI scan results. Prenuvo, the Silicon Valley-based company behind the scan, had detected a nodule in her lungs, prompting immediate follow-up procedures.
Santarosa, a spinal access surgeon, hadn’t experienced specific symptoms, but a gut feeling, combined with a sense of being “off” since in vitro fertilization, led her to undergo the scan after seeing a Prenuvo ad on Facebook.
The demand for Prenuvo’s full-body MRI scans, capable of identifying over 500 conditions such as cancer, multiple sclerosis, and brain aneurysms, has surged.
Celebrities like Kim Kardashian endorse it as a “life-saving machine,” and investors include Cindy Crawford, Eric Schmidt, Anne Wojcicki, and Tony Fadell. The company raised $70 million in a funding round led by Felicis Ventures in the previous year.
Prenuvo’s CEO, Andrew Lacy, aims to provide customers with a deeper understanding of their health by revealing what’s happening beneath the skin. However, the scans are currently not covered by insurance, requiring patients to pay out of pocket.
Despite the out-of-pocket expense, Santarosa considered the imaging worth every penny, as her cancer was detected early, eliminating the need for extensive treatments like chemotherapy or radiation.
Traditional MRI scans are typically ordered by doctors and can take over an hour, focusing on specific body parts. In contrast, Prenuvo’s custom MRI machines, FDA-cleared in 2018, can scan the entire body in about an hour.
The images are then reviewed by licensed radiologists, with results usually delivered within five to 10 business days. Such efficiency has led to long waitlists, indicating a growing awareness and demand for the service.
To address the issue of accessibility, Prenuvo plans to open 11 more locations by 2024, including international sites in London and Sydney. Despite the high demand, the company is actively working on reducing costs through traditional scaling methods.
Some companies have started offering Prenuvo scans as an employee benefit, contributing to increased access. Lacy believes that data collected over time will help inform traditional insurance companies about potential coverage options.
Prenuvo’s focus on bringing prices down is complemented by efforts to leverage artificial intelligence and reduce scan durations further. The cost is directly related to the time customers spend in the machines, and the company is exploring ways to make the technology more cost-effective.
However, challenges in the radiology field, such as burnout and a potential shortage of radiologists, loom large. Prenuvo, fortunately, has a backlog of radiologists eager to work for the company, as early detection provides a positive shift from diagnosing advanced diseases.
While Prenuvo’s success in catching conditions like stage 1 cancer has garnered praise, medical experts emphasize the need for realistic expectations. Full-body MRI scans, despite their capabilities, are not a replacement for targeted screenings like colonoscopies and mammograms.
Dr. Jasnit Makkar from Columbia University Medical Center emphasizes that the technology is a tool for physicians and patients but should not replace comprehensive diagnostic examinations.
The limitations of full-body MRI scans include challenges in identifying lesions in certain areas, such as the lungs, and the necessity for different techniques when scanning diverse body parts. Dr. Kimberly Amrami from Mayo Clinic Rochester highlights the need to set patient expectations accordingly, as there is no one-size-fits-all approach for MRI scans.
Prenuvo distinguishes itself by not using contrast, a heavy metal injected into blood vessels during traditional MRI scans. While contrast can enhance visualization, Prenuvo’s hardware aims to achieve similar results without it. The controversy surrounding contrast usage and the company’s commitment to a screening solution for normal-risk and asymptomatic patients guide their approach.
Lacy acknowledges the ongoing dialogue between patients and physicians to determine the most suitable imaging method, emphasizing that MRI is not a one-size-fits-all solution. Prenuvo’s commitment to leveraging technology, addressing cost concerns, and collaborating with the medical community positions it as a key player in the evolving landscape of early disease detection.
As the company expands globally and refines its approach, the intersection of advanced technology and personalized healthcare is poised to reshape the future of diagnostic imaging.
